Statements (70)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:biotechnology
|
| gptkbp:acquisition |
Acquired by a larger pharmaceutical company
|
| gptkbp:advocacy |
engaged in outreach efforts.
|
| gptkbp:annual_report |
files with SEC
|
| gptkbp:business_model |
focused on drug development
|
| gptkbp:ceo |
gptkb:M._Scott_Saag
|
| gptkbp:clinical_trial |
Phase 3 trials
I, II, and III published in scientific journals conducts clinical trials measured in trials monitored for compliance for multiple diseases reported to regulatory agencies tailored to specific therapies |
| gptkbp:collaboration |
academic institutions
|
| gptkbp:collaborations |
with other biotech firms
with other biotech companies |
| gptkbp:collaborative_projects |
with research institutions
|
| gptkbp:collaborative_research_agreements |
with universities
|
| gptkbp:drug_candidates |
targeting specific receptors
|
| gptkbp:drug_development_process |
follows FDA guidelines
|
| gptkbp:drug_safety |
monitored post-approval
|
| gptkbp:efficacy_studies |
conducted for drug candidates
|
| gptkbp:employees |
approximately 50
|
| gptkbp:financial_performance |
publicly reported quarterly earnings
|
| gptkbp:focus |
therapeutics for cancer and other serious diseases
|
| gptkbp:founded |
gptkb:1997
|
| gptkbp:founder |
gptkb:M._Scott_Saag
|
| gptkbp:funding |
secured from grants
|
| gptkbp:has_advisory_board |
composed of industry experts
|
| gptkbp:head_of_state |
focused on strategic growth
|
| gptkbp:headquarters |
gptkb:Memphis,_Tennessee
|
| https://www.w3.org/2000/01/rdf-schema#label |
GTx, Inc.
|
| gptkbp:industry |
gptkb:pharmaceuticals
|
| gptkbp:instruction_set |
multiple drug candidates
|
| gptkbp:invention |
holds multiple patents
|
| gptkbp:investment |
held regularly
various venture capital firms provides updates to shareholders in research and development |
| gptkbp:is_tested_for |
identified for treatment response
|
| gptkbp:leadership |
experienced management team
|
| gptkbp:market |
conducted for product positioning
|
| gptkbp:market_cap |
varies with stock price
|
| gptkbp:marketing_strategy |
targeting specific patient populations
|
| gptkbp:partnership |
various pharmaceutical companies
|
| gptkbp:partnerships |
with healthcare organizations
established for better access to markets |
| gptkbp:product |
gptkb:Ostarine
gptkb:Enobosarm |
| gptkbp:publications |
contributes to peer-reviewed journals
|
| gptkbp:recruitment |
for clinical trials
|
| gptkbp:regulatory_compliance |
FDA approval for certain products
ensured throughout development process files for drug approvals |
| gptkbp:research |
drives product development
|
| gptkbp:research_areas |
hormonal therapies
in various stages of development androgen receptor antagonists |
| gptkbp:research_focus |
oncology
muscle wasting disorders |
| gptkbp:safety_features |
assessed in trials
|
| gptkbp:stock_exchange |
gptkb:NASDAQ
traded on NASDAQ |
| gptkbp:stock_symbol |
GTXI
|
| gptkbp:therapeutic_innovations |
aimed at improving patient outcomes
|
| gptkbp:website |
www.gtxinc.com
|
| gptkbp:bfsParent |
gptkb:Ostarine
|
| gptkbp:bfsLayer |
7
|